ACH-4471 in trials for PNH treatment
Achillion Pharmaceuticals is sponsoring a tiny Phase II trial of ACH-4471, a new drug for the treatment of PNH.
ACH-4471 inhibits a specific molecule that is part of the complement process, and may reduce hemolysis. ACH-4471 was recently approved in Europe for treatment of C3 glomerulopathy. |
All times are GMT -4. The time now is 01:24 AM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org